CD274 and melanoma: Durable benefits observed in melanoma, NSCLC, and RCC suggest that ongoing PD-(L)1 blockade can preserve immunologic memory and counteract resistant subclones, thereby distinguishing immunotherapy from earlier paradigms of treatment continuation.